IDNA Fact Sheet: iShares Genomics Immunology and Healthcare ETF
Share
$37.00
close, Nov 20, 2026
Over the year to Nov 19, 2026, IDNA returned +47.2% in total and charged 0.47% a year.
- 1-year total return
- +44.7%
- to Nov 20, 2026
- Expense ratio
- 0.47%
- a year
- Net assets
- $320m
- on Nov 19, 2026
- Net flow, last 5 trading days
- +$4.1m
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
IDNA $14,724 +47.2% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−13.3%
3 months−7.7%
Year to date+41.9%
1 year+44.7%
3 years+92.5%
5 years−18.6%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
MODERNA13.00%
GENMAB6.45%
TWIST BIOSCIENCE4.99%
REGENERON PHARMACEUTICALS4.50%
BAYER AG4.45%
TAKEDA PHARMACEUTICAL4.37%
EXELIXIS INC3.86%
VERTEX PHARMACEUTICALS3.61%
ROCHE PS PAR AG3.56%
INCYTE CORP3.50%
IDNA top ten by weight, 52.3% of the fund, of its 51 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 51 stocks in genomics and gene editing, 28% of its weight in S&P 500 companies · First traded Jun 13, 2019 · Benchmark Its own holdings, as of Nov 19, 2026